Natera Publishes VALID Study Results for Prospera Lung dd-cfDNA Transplant Rejection Assessment Test
/PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of the VALID study1, showcasing its...
Source: prnewswire.com